Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

1. The benefits and harms of aspirin for people with type 2 diabetes are finely balanced

The benefits and harms of aspirin for people with type 2 diabetes are finely balanced Aspirin benefits and harms balanced in type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover The benefits and harms of aspirin for people with type 2 diabetes are finely balanced Published on 4 December 2018 doi: Daily aspirin reduced the risk of serious vascular events among people with diabetes, while increasing the risk of major bleeding to a similar extent. Aspirin prevented one person (...) that aspirin shouldn’t be prescribed to people with diabetes who do not have existing cardiovascular disease. Share your views on the research. Why was this study needed? Cardiovascular disease is the leading cause of death in the UK. It accounted for 152,465 deaths in 2016, of which 66,076 deaths were from coronary heart disease and 37,771 from stroke. Around 4 million people in the UK have diabetes, mostly type 2. Adults with diabetes are two to three times more likely to develop cardiovascular disease

NIHR Dissemination Centre2018

2. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.

Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. OBJECTIVE: To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes. DESIGN: Population based cohort study. SETTING: General practices contributing data to the UK Clinical Practice Research Datalink. PARTICIPANTS: 154 162 (...) , respectively). CONCLUSION: Compared with use of other second or third line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

BMJ2018

3. Rotating night shift work and adherence to unhealthy lifestyle in predicting risk of type 2 diabetes: results from two large US cohorts of female nurses.

Rotating night shift work and adherence to unhealthy lifestyle in predicting risk of type 2 diabetes: results from two large US cohorts of female nurses. OBJECTIVES: To prospectively evaluate the joint association of duration of rotating night shift work and lifestyle factors with risk of type 2 diabetes risk, and to quantitatively decompose this joint association to rotating night shift work only, to lifestyle only, and to their interaction. DESIGN: Prospective cohort study. SETTING: Nurses (...) ' Health Study (1988-2012) and Nurses' Health Study II (1991-2013). PARTICIPANTS: 143 410 women without type 2 diabetes, cardiovascular disease, or cancer at baseline. EXPOSURES: Rotating night shift work was defined as at least three night shifts per month in addition to day and evening shifts in that month. Unhealthy lifestyles included current smoking, physical activity levels below 30 minutes per day at moderate to vigorous intensity, diet in the bottom three fifths of the Alternate Healthy Eating

BMJ2018 Full Text: Link to full Text with Trip Pro

4. ‘Artificial pancreas’ improves glucose control in hospital patients with type 2 diabetes

with type 2 diabetes admitted to hospital for non-critical care. Those using the system spent about six hours longer in the target range, and this could hasten their recovery and reduce staff workload. The number of hospitalised patients with type 2 diabetes is increasing. Glucose control often worsens during illness. Closed-loop pumps have been shown to improve blood glucose control in type 1 diabetes and in critical care settings. This two-centre study included 136 patients with type 2 diabetes on general (...) glucose (hyperglycaemia) and low (hypoglycaemia) can delay recovery and increase the risk of complications. However, illness, medication and changes in routine, such as mealtimes, can make it difficult to maintain blood glucose targets. A Canadian review of 20 studies showed that a newer closed-loop insulin pump, also known as an artificial pancreas, increased the time that patients with type 1 diabetes spent in the target blood glucose range, and decreased the risk of severe hypoglycaemia. This study

NIHR Dissemination Centre2018

5. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. BACKGROUND: The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS: We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse (...) % in the placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001). CONCLUSIONS: In patients with type 2 diabetes who had or were at risk

NEJM2018

6. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

(absolute incidence rate difference, 0.22 [95% CI, -0.52 to 0.97] per 100 person-years) (HR, 1.04; 95% CI, 0.89-1.22; P = .62). Adverse events occurred in 2697 (77.2%) and 2723 (78.1%) patients in the linagliptin and placebo groups; 1036 (29.7%) and 1024 (29.4%) had 1 or more episodes of hypoglycemia; and there were 9 (0.3%) vs 5 (0.1%) events of adjudication-confirmed acute pancreatitis. Conclusions and Relevance: Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual (...) Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. Importance: Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4) inhibitors but have included limited numbers of patients with high CV risk and chronic kidney disease. Objective: To evaluate the effect of linagliptin

JAMA2018

7. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. BACKGROUND: The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined. METHODS: We did a systematic review and meta-analysis of randomised, placebo-controlled (...) , cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes. We searched PubMed and Embase for trials published up to Sept 24, 2018. Data search and extraction were completed with a standardised data form and any discrepancies were resolved by consensus. Efficacy outcomes included major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death), the composite of cardiovascular death or hospitalisation for heart failure, and progression of renal disease. Hazard ratios

Lancet2018

9. Semaglutide (Ozempic) - for the treatment of insufficiently controlled type 2 diabetes mellitus

Semaglutide (Ozempic) - for the treatment of insufficiently controlled type 2 diabetes mellitus %PDF-1.5 %���� 54 0 obj > endobj 69 0 obj >/Filter/FlateDecode/ID[ ]/Index[54 24]/Info 53 0 R/Length 77/Prev 192641/Root 55 0 R/Size 78/Type/XRef/W[1 2 1]>>stream h�bbd``b`j�S@D�`�gAD3Hv*��D >stream h�b``�e``*e7n0�F fa�h@�bF%!�� lkbH&��0c�p�~�r��a͚P3�n����|n ���(� @���� endstream endobj 55 0 obj >/Metadata 2 0 R/PageLayout/OneColumn/Pages 52 0 R/StructTreeRoot 6 0 R/Type/Catalog>> endobj 56 0 obj (...) ������\ 5'�O����@��>qD!�@�����|�ET0���R�����Y����p�����;�c��2,� �Z��v�x�� dB��s�3�={���ۼ��� �2R���G�-�`\� ׇ�6^qŅl�d�X��'�;��"�a ��f�. xV;z� 2����?�m�0�����Ȣ��x���f�� �3]:�Ʉ��q��1n�L���1&�y�c5���J��7�g���z�x�'7�̈́w�9�ۗ��F�Pn��s ;�QB i6������X =޸��$&�4�/&�E�OkT��e�A�c�J���P��_8*�rqc��� $�MH����I=b����Œ��z�ǹ=p��g��tIl����_v;�P�vz7h���Mɘ0@���O�藯ߤ����(��4z� ��_�\���!i�g�X�dA�G�!6����J��[��$lu�3�I4_��85��2ϼx��Pj�����NJ�t��|`B�h{��(U� '�t��v�ظ�dٶ=�@� @e�H�Ҳ !�hʼs���dm��i��$�֨�Ô��*��.ʀ]�+"�R���w������y���KD

All Wales Medicines Strategy Group2018

10. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial

Health-related quality of life in people with type 2 diabetes participating in the LEADER trial 30260088 2018 10 25 1463-1326 2018 Sep 27 Diabetes, obesity & metabolism Diabetes Obes Metab Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. 10.1111/dom.13547 To assess health-related quality of life (HRQoL) in people with type 2 diabetes (T2D) participating in the LEADER cardiovascular outcomes trial using the five-dimension European Quality (...) of life liraglutide patient-reported outcomes type 2 diabetes 2018 05 18 2018 09 07 2018 09 23 2018 9 28 6 0 2018 9 28 6 0 2018 9 28 6 0 aheadofprint 30260088 10.1111/dom.13547

EvidenceUpdates2018

11. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial

Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial 30259644 2018 11 14 1463-1326 20 12 2018 Dec Diabetes, obesity & metabolism Diabetes Obes Metab Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. 2885-2893 10.1111/dom.13545 To evaluate the efficacy and safety (...) of mealtime or post-meal fast-acting insulin aspart (faster aspart) vs mealtime insulin aspart (IAsp), both in combination with insulin degludec, in participants with type 1 diabetes (T1D). This multicentre, treat-to-target trial (Clinical trial registry: NCT02500706, ClinicalTrials.gov) randomized participants to double-blind mealtime faster aspart (n = 342) or IAsp (n = 342) or open-label post-meal faster aspart (n = 341). The primary endpoint was change from baseline in HbA1c 26 weeks post

EvidenceUpdates2018

12. Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort

Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort 30254082 2018 09 26 1935-5548 2018 Sep 25 Diabetes care Diabetes Care Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort. dc180625 10.2337/dc18-0625 To evaluate the prevalence of hearing impairment in participants with type 1 diabetes (...) enrolled in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study and compare with that of a spousal control group without diabetes. Among participants with type 1 diabetes, to evaluate the association of hearing impairment with prior DCCT therapy and overall glycemia. DCCT/EDIC participants ( n = 1,150) and 288 spouses without diabetes were recruited for the DCCT/EDIC Hearing Study. All subjects completed a self-administered

EvidenceUpdates2018

13. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials 30287422 2018 10 05 1935-5548 2018 Oct 04 Diabetes care Diabetes Care Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. dc181749 10.2337/dc18-1749 To evaluate the safety and efficacy of empagliflozin 10- and 25-mg doses plus a unique lower dose (2.5 mg) as adjunct to intensified insulin in patients with type 1 diabetes (T1D). The EASE (Empagliflozin as Adjunctive to inSulin (...) thErapy) program ( N = 1,707) included two double-blind, placebo-controlled phase 3 trials: EASE-2 with empagliflozin 10 mg ( n = 243), 25 mg ( n = 244), and placebo ( n = 243), 52-week treatment; and EASE-3 with empagliflozin 2.5 mg ( n = 241), 10 mg ( n = 248), 25 mg ( n = 245), and placebo ( n = 241), 26-week treatment. Together they evaluated empagliflozin 10 mg and 25 mg, doses currently approved in treatment of type 2 diabetes, and additionally 2.5 mg on 26-week change in glycated hemoglobin

EvidenceUpdates2018

14. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial

pressure and heart rate in patients with hypertension (pre- and stage 1 hypertension) and inadequately controlled Type 2 diabetes (glycated haemoglobin 7%-10% [53-86 mmol/mol]). Eligible patients for this investigator-initiated, parallel-group, randomized, double-blind trial were on stable background antihyperglycaemic therapy excluding insulin, glucagon-like peptide-1 receptor agonists and dipeptidyl-peptidase-4 inhibitors. Participants were centrally randomized in a 1:1 ratio to daily liraglutide 0.6 mg (...) Thessaloniki, Thessaloniki, Greece. Harris Manchester College, University of Oxford, Oxford, UK. eng Novo Nordisk Journal Article 2018 09 22 England Diabetes Obes Metab 100883645 1462-8902 GLP-1 liraglutide randomized trial type 2 diabetes 2018 08 07 2018 09 11 2018 09 17 2018 9 23 6 0 2018 9 23 6 0 2018 9 23 6 0 aheadofprint 30242948 10.1111/dom.13541

EvidenceUpdates2018

15. Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study

(American College of Rheumatology criteria) and type 2 diabetes mellitus (HbA1c 6.5-9.0% [48-75 mmol/mol]; 1-2 oral hypoglycaemic agents) were treated with intra-articular TA-ER (32 mg n = 18) or TAcs 40 mg (n = 15). Continuous glucose monitoring-measured glucose (CGMG) was assessed from 1 week pre-injection through 2 weeks postinjection. Endpoints included change in average daily CGMG from baseline (days -3 to -1) to days 1-3 postinjection (CGMGdays1-3) (primary) and percent time average hourly CGMG (...) Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study 30203101 2018 09 11 1462-0332 2018 Sep 06 Rheumatology (Oxford, England) Rheumatology (Oxford) Triamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study. 10.1093/rheumatology/key265 Approximately 30% of patients with type 2 diabetes mellitus have knee osteoarthritis. IA corticosteroids used to manage

EvidenceUpdates2018

16. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen

A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen 30160030 2018 10 03 1463-1326 2018 Aug 29 Diabetes, obesity & metabolism Diabetes Obes Metab A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals (...) with type 2 diabetes on a basal-only insulin regimen. 10.1111/dom.13515 The EDITION trials in type 2 diabetes demonstrated comparable glycaemic control with less nocturnal and anytime (24-hour) hypoglycaemia for insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100). However, the predefined nocturnal window (0:00-5:59 AM) may not be the most relevant for clinical practice. This post-hoc analysis compared expansions of the predefined nocturnal interval during basal insulin treatment without prandial

EvidenceUpdates2018

17. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial

Pharmaceutical Company Ltd, Shanghai, China. Yang Jun J Lilly Suzhou Pharmaceutical Company Ltd, Shanghai, China. eng Eli Lilly and Company Journal Article 2018 08 21 England Diabetes Obes Metab 100883645 1462-8902 GLP-1 analogue dulaglutide type 2 diabetes 2018 04 26 2018 08 09 2018 08 10 2018 8 22 6 0 2018 8 22 6 0 2018 8 22 6 0 aheadofprint 30129089 10.1111/dom.13506 (...) Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial 30129089 2018 10 08 1463-1326 2018 Aug 21 Diabetes, obesity & metabolism Diabetes Obes Metab Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label

EvidenceUpdates2018

18. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study 30352894 2018 10 24 1935-5548 2018 Oct 23 Diabetes care Diabetes Care Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. dc181087 10.2337/dc18-1087 This study evaluated the long-term safety and efficacy of dapagliflozin as an adjunct to adjustable insulin in patients with type 1 diabetes and inadequate (...) glycemic control. DEPICT-1 (Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes) was a randomized (1:1:1), double-blind, placebo-controlled Phase 3 study of dapagliflozin 5 mg and 10 mg in patients with type 1 diabetes (HbA 1c , 7.5-10.5% [58-91 mmol/mol]) (NCT02268214). The results of the 52-week study, consisting of the 24-week short-term and 28-week extension period, are reported here. Of the 833 patients randomized into the study, 708 (85%) completed the 52-week study

EvidenceUpdates2018

19. Nine different drug classes reviewed for type 2 diabetes

, 0.12 [95% CI, 0.08 to 0.18]; RD, -22% [-27% to -18%]). When added to metformin and sulfonylurea, GLP-1 receptor agonists were associated with the lowest odds of hypoglycemia (OR, 0.60 [95% CI, 0.39 to 0.94]; RD, -10% [95% CI, -18% to -2%]). CONCLUSIONS AND RELEVANCE: Among adults with type 2 diabetes, there were no significant differences in the associations between any of 9 available classes of glucose-lowering drugs (alone or in combination) and the risk of cardiovascular or all-cause mortality (...) Nine different drug classes reviewed for type 2 diabetes Signal - Nine different drug classes reviewed for type 2 diabetes Dissemination Centre Discover Portal NIHR DC Discover Nine different drug classes reviewed for type 2 diabetes Published on 17 January 2017 Metformin worked best at keeping blood sugar levels under control and remains a good first choice as single therapy. Overall, the nine classes of blood sugar-lowering drugs had similar effect on risk of death from cardiovascular causes

NIHR Dissemination Centre2018

20. Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously

Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously Signal - Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously Dissemination Centre Discover Portal NIHR DC Discover Fewer large babies are born to pregnant woman with type 1 diabetes if their glucose was monitored continuously Published on 12 December 2017 Pregnant women with type 1 diabetes who used a continuous glucose (...) diabetic control over 12 weeks, only improved slightly. This may be unsurprising because HbA1c results are less reliable in pregnancy and women found it hard to stick to the continuous monitoring protocol. Strict control of blood glucose levels during pregnancy reduces the risk for women with type 1 diabetes, and their babies are less likely to be large or need treatment for low blood glucose. Continuous monitoring provides many readings but requires the user to deliver insulin accordingly. Motivated

NIHR Dissemination Centre2018